Safety and Clinical Experience of XPO1 Inhibitors in R/R MM Patients
January 19th 2024Dr. Usmani, MD, MBA, FACP provides insights into Selinexor's safety profile in Relapsed/Refractory Multiple Myeloma (R/R MM), comparing it with other treatments and delve into the ongoing challenges and unmet needs in R/R MM patient care.
Read More
Treatment Strategies in Triple Class Refractory MM Patients
January 19th 2024An expert explores factors influencing the selection of treatment regimens in relapsed, triple class refractory multiple myeloma (MM) patients, with a focus on prophylactic measures for managing adverse events associated with novel agents like Selinexor, bispecific, and CAR-T therapies.
Read More
Highlights from ASH 2023 in Transplant-Eligible NDMM
January 15th 2024Experts in multiple myeloma discuss highlights from the ASH 2023 meeting around transplant-eligible NDMM with particular focus on the PERSEUS and GRIFFIN trials and the clinical implications of the results of these studies.
Read More